

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA: Venetoclax in combination with rituximab for treating relapsed or refractory chronic lymphocytic leukaemia [ID1097]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No equality issues have been identified.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

Not applicable.

Approved by Associate Director (name): Frances Sutcliffe

Date: 17/04/2018

Technology Appraisals: Scoping
Equality impact assessment for the single technology appraisal of venetoclax in combination with rituximab for treating relapsed or refractory chronic lymphocytic leukaemia
Issue date: April 2018